iProgen and Korean Basic Science Institute (KBSI) launches ADC research collaboration to treat Osteoporosis using Antibody Drug Conjugate technology

Korean Basic Science Institute (KBSI) and iProgen Biotech Inc. enters research collaboration to explore the application of Antibody Drug Conjugate technology to treat Osteoporosis. iProgen Biotech will engineer ADC candidates and KBSI will evaluate the effect of the candidate ADCs in treating Osteoporosis.